5 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 3, 2 Phase 1, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Completed 2 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Relapsing Multiple Sclerosis (RMS): new trials by email Literature Review of Relapsing Multiple Sclerosis (RMS) trials Research Report on Relapsing Multiple Sclerosis (RMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab Ofatumumab approved dose, Ofatumumab new dose - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 196 | 2025-03-13 | 2026-08-10 |
| Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study Ofatumumab - Relapsing Multiple Sclerosis (RMS) | Recruiting | Novartis Pharmaceuticals | 160 | 2024-12-10 | 2026-06-11 | |
| A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate - Relapsing Multiple Sclerosis (RMS) | Phase 4 | Terminated | Novartis Pharmaceuticals | 24 | 2021-06-10 | 2025-05-16 |
| Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients Fingolimod 0.5mg - Relapsing Multiple Sclerosis (RMS) | Phase 4 | Completed | Novartis Pharmaceuticals | 98 | 2021-02-20 | 2026-01-13 |
| An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Ublituximab - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Active not recruiting | TG Therapeutics, Inc. | 1100 | 2019-11-18 | 2026-10-30 |
| Effects of Cladribine Tablets on the PK of Microgynon® Cladribine, Placebo, Microgynon® - Relapsing Multiple Sclerosis (RMS) | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 28 | 2019-01-17 | 2024-03-15 |
| Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Ublituximab, Teriflunomide, Oral Placebo - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Completed | TG Therapeutics, Inc. | 549 | 2017-09-19 | 2021-12-06 |
| Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Ublituximab, Teriflunomide, Oral Placebo - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Completed | TG Therapeutics, Inc. | 545 | 2017-08-25 | 2021-12-06 |
| Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS) Rebif (Interferon beta-1a) - Relapsing Multiple Sclerosis (RMS) | Completed | Merck KGaA, Darmstadt, Germany | 594 | 2016-06-30 | 2022-04-04 |
Multiple Sclerosis (3) · Autoimmune Diseases (1) · COVID-19 (1) · Coronavirus Infections (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases of the Nervous System (3) · Demyelinating Autoimmune Diseases, CNS (3) · Demyelinating Diseases (3) · Immune System Diseases (3) · Nervous System Diseases (3) · Autoimmune Diseases (2) · Chronic Disease (1) · Coronaviridae Infections (1) · Disease Attributes (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Pneumonia (1)
ublituximab (3) · ofatumumab (2) · teriflunomide (2) · CVnCoV COVID-19 vaccine (1) · Cladribine (1) · Fingolimod Hydrochloride (1) · Glatiramer Acetate (1) · Interferon beta-1a (1) · Interferons (1) · ethinyl estradiol, levonorgestrel drug combination (1)
Novartis Pharmaceuticals (4) · TG Therapeutics, Inc. (3) · Merck KGaA, Darmstadt, Germany (2) · Cabaletta Bio (1)
United States (5) · Poland (3) · Algeria (1) · Argentina (1) · Bahrain (1) · Belarus (1) · Bulgaria (1) · China (1) · Croatia (1) · Egypt (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Iran (1)
PMID 36001711, PMID 39512280, PMID 41787239, PMID 42292352, PMID 38090266, PMID 41697690
2017 (2), 2018 (1), 2019 (1)